Surgery After Chemotherapy and Immunotherapy for Advanced Lung Cancer
Part of Cancer, Lungs & breathing clinical trials.
This study follows patients with advanced non-small cell lung cancer (NSCLC) who receive combination chemotherapy and immunotherapy before surgery. Researchers will track how well surgery works after this pre-surgical treatment and compare different surgical approaches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with non-small cell lung cancer (NSCLC) that is stage IIB or III without spread to distant sites
- Planned to receive chemotherapy combined with an immunotherapy drug (PD-1 or PD-L1 inhibitor) before surgery with curative intent
- Completed at least one cycle of the chemotherapy-immunotherapy combination
- Had chest imaging (CT scan, with or without PET scan) before treatment started and again 2-6 weeks after the last treatment dose
- Planning to have surgery 2-10 weeks after completing pre-surgical treatment
- Good overall health status (ECOG performance score 0-2) and able to complete 90 days of follow-up after surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining immunotherapy with chemotherapy before robot-assisted lung surgery improves outcomes for patients with stage II–III non-small cell lung cancer. The goal is to shrink the tumor before surgery and then remove it completely using minimally invasive robotic techniques.
This trial tests a combination of radiation therapy, an immunotherapy drug called toripalimab, and chemotherapy given before surgery for stage II-III non-small cell lung cancer. The goal is to shrink the tumor before removal and improve survival outcomes.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
This trial tests a combination of targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib) given before surgery for people with a certain type of lung cancer that has not spread too far. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial studies a comprehensive treatment approach for lung cancer that combines immunotherapy given before surgery with standard surgery. It aims to understand how well this approach works by analyzing your medical data and samples.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
Hear when a new Neoadjuvant Chemoimmunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.